Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius    FRE   DE0005785604

FRESENIUS

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Expects to Miss 2020 Targets on Revised 2019 Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 02:32am EDT

By Patrick Costello

Fresenius adjusted its mid-term guidance late on Thursday, saying the company no longer expects to meet group targets for 2020 after updating its forecast for next year.

The German health-care company said it expects to see mid-single-digit organic sales growth for 2019, with net income remaining "broadly stable" from 2018.

The company's previously expected group sales to increase at a compounded annual growth rate of 7.1% to 10.3% through 2020, with group net income increasing at a CAGR of 8.3% to 12.6%.

Fresenius said it expects to generate sustainable organic sales growth in the mid-single-digit range from 2020 onward, with group net income expected to grow faster than sales on an organic basis.

Among the group's individual units, Fresenius Medical Care--a provider of dialysis products and services--should generate sales growth and net income in 2019 in line with the levels recorded in 2018, the company said.

It forecasts that the Fresenius Kabi division--an essential drugs and medical device supplier--will deliver mid-single-digit organic sales growth and "low- to mid-single-digit" growth in earnings before interest and taxes next year.

Fresenius Helios, the group's hospital operator unit, expects EBIT to contract at a low- to mid-single digit rate next year, as growth in Spain will be unlikely to offset "headwinds" in Germany resulting from regulatory changes, Fresenius SE said.

The group said it expects to propose a dividend increase for 2018 in line with earnings growth, as well as a further dividend increase in 2019.

The company will release detailed financial guidance for 2019 and on its mid-term targets alongside full-year results for 2018 on Feb. 20.

Write to Patrick Costello at patrick.costello@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS 1.22% 47.725 Delayed Quote.11.26%
FRESENIUS MEDICAL CARE 0.17% 69.08 Delayed Quote.21.75%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS
05/20FRESENIUS : Ex-dividend day for final dividend
FA
05/17ANNUAL GENERAL MEETING : Fresenius on course for continued growth, 26th straight..
PU
05/16FRESENIUS : Medical Care stays on course for growth – Annual General Meeti..
PU
05/03FRESENIUS SE & CO. KGAA : Notification and public disclosure of transactions by ..
EQ
05/02Fresenius makes solid start to year after turbulent 2018
RE
05/02FRESENIUS : makes solid start to 2019 and confirms Group guidance
PU
05/02FRESENIUS : Backs Guidance After Sales, Operating Profit Rose in 1Q
DJ
04/30FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
04/29PAUL ACHLEITNER : Deutsche Bank's Achleitner best-paid chairman of German compan..
RE
04/23FRESENIUS : Helios becomes medical partner at Rafa Nadal Academy
PU
More news
Financials (€)
Sales 2019 35 217 M
EBIT 2019 4 683 M
Net income 2019 1 884 M
Debt 2019 17 569 M
Yield 2019 1,73%
P/E ratio 2019 14,12
P/E ratio 2020 13,07
EV / Sales 2019 1,24x
EV / Sales 2020 1,14x
Capitalization 26 134 M
Chart FRESENIUS
Duration : Period :
Fresenius Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS
Short TermMid-TermLong Term
TrendsBearishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 58,1 €
Spread / Average Target 24%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
FRESENIUS11.26%29 147
AIER EYE HOSPITAL GROUP CO LTD--.--%12 651
BANGKOK DUSIT MEDICAL SERVICES PCL--.--%12 375
IHH HEALTHCARE BHD--.--%11 450
RAMSAY HEALTH CARE LIMITED20.06%9 666
HAPVIDA PARTICIPACOES E INVESTIMENTOS SA17.34%5 906